At Gilead Sciences, they’re popping champagne corks. They’ve got a blockbuster drug, a once in a lifetime winner, Sovaldi. As FiercePharma reports:
“With a revolutionary approach to hepatitis C and a price tag of $84,000 per 12-week treatment course, analysts expected big sales from Gilead’s Sovaldi. Some even forecast it would reach $9 billion or more by 2017, at which level it would surpass Pfizer’s Lipitor to take the crown for biggest-selling drug of all time. But none expected the exponential growth the drug is posting right now…”
A drug for hepatitis C. What a drug, what a price. $84,000 for 12 weeks of treatment.
So…what is hepatitis C?
Back in the day, there was one US mainstream reporter who wrote unflinchingly about medical matters. The late Nick Regush, at ABC News. He had serious questions about hepatitis C.
Join us on our
Share this page with your friends
on your favorite social network: